Research and Nonresearch Industry Payments to Nephrologists in the United States between 2014 and 2021
暂无分享,去创建一个
[1] Akihiko Ozaki,et al. Trend in industry payments to infectious disease physicians in the United States: a seven-year analysis of nonresearch payments from the Open Payments Database between 2014 and 2020 , 2022, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[2] Akihiko Ozaki,et al. Industry payments to allergists and clinical immunologists in the United States during the coronavirus disease 2019 pandemic , 2022, Annals of Allergy, Asthma & Immunology.
[3] Garrett S. Booth,et al. Assessment of the Use of Sex and Gender Terminology in US Federal, State, and Local Databases. , 2022, JAMA internal medicine.
[4] R. Rosenblatt,et al. Trends in Industry Payments to Gastroenterologists and Hepatologists in the United States from 2014 to 2020. , 2022, Gastroenterology.
[5] Akihiko Ozaki,et al. Evaluation of Conflicts of Interest among Participants of the Japanese Nephrology Clinical Practice Guideline , 2022, Clinical journal of the American Society of Nephrology : CJASN.
[6] Akihiko Ozaki,et al. Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019 , 2022, medRxiv.
[7] Akihiko Ozaki,et al. Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019 , 2022, Blood Cancer Journal.
[8] Arif Subhan. Centers for Medicare & Medicaid Services , 2021, Journal of Clinical Engineering.
[9] Saritha Ranabothu,et al. Industry Payments to Nephrologists in the United States , 2021, Cureus.
[10] C. Crowson,et al. Industry Payments to Practicing US Rheumatologists, 2014–2019 , 2021, Arthritis & rheumatology.
[11] J. Schold,et al. “What do you think about nephrology?” A national survey of internal medicine residents , 2021, BMC Nephrology.
[12] S. Herrmann,et al. Self-reported Financial Conflict of Interest in Nephrology Clinical Practice Guidelines , 2020, Kidney international reports.
[13] Akihiko Ozaki,et al. Financial payments made by pharmaceutical companies to the authors of Japanese hematology clinical practice guidelines between 2016 and 2017. , 2020, Health policy.
[14] W. Kitzmiller,et al. Gender Disparity in 2013-2018 Industry Payments to Plastic Surgeons. , 2020, Aesthetic surgery journal.
[15] G. Schett,et al. Key opinion leaders — a critical perspective , 2020, Nature Reviews Rheumatology.
[16] Aaron P. Mitchell,et al. Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? , 2020, Annals of Internal Medicine.
[17] Akihiko Ozaki,et al. Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan , 2020, PloS one.
[18] D. Velez,et al. Gender disparities in industry payments to urologists. , 2020, Urology.
[19] A. Dunn,et al. Financial ties between leaders of influential US professional medical associations and industry: cross sectional study , 2020, BMJ.
[20] F. Mallamaci,et al. Paving the way towards gender equality: how are we faring in nephrology? , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[21] S. Mehra,et al. Industry Payments for Otolaryngology Research: A Four‐Year Analysis of the Open Payments Database , 2020, The Laryngoscope.
[22] B. Jacobs,et al. Gender Gap in Industry Relationships and Scholarly Impact Among Academic Urologists in the United States. , 2020, Urology.
[23] M. Vaduganathan,et al. Gender differences in industry payments among cardiologists. , 2019, American heart journal.
[24] Joseph S. Puthumana,et al. Investigating the gender pay gap in industry contributions to academic neurosurgeons. , 2019, World neurosurgery.
[25] J. Bernat,et al. Scope and nature of financial conflicts of interest between neurologists and industry , 2019, Neurology.
[26] A. Webster,et al. Barriers to the Professional Advancement of Women in Nephrology. , 2019, Clinical journal of the American Society of Nephrology : CJASN.
[27] P. Lichter,et al. Characteristics of Industry Payments to Ophthalmologists in the Open Payments Database. , 2019, JAMA ophthalmology.
[28] Brian Uzzi,et al. Comparison of National Institutes of Health Grant Amounts to First-Time Male and Female Principal Investigators , 2019, JAMA.
[29] K. Bielefeldt,et al. Assessment of Pharmaceutical Company and Device Manufacturer Payments to Gastroenterologists and Their Participation in Clinical Practice Guideline Panels , 2018, JAMA network open.
[30] L. Wilkins. Financial relationships between neurologists and industry: The 2015 Open Payments database , 2018, Neurology.
[31] E. Lederer. Women in Nephrology Today. , 2018, Clinical journal of the American Society of Nephrology : CJASN.
[32] P. Narayanaswami,et al. Financial relationships between neurologists and industry , 2018, Neurology.
[33] Daniel M. Hartung,et al. Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin , 2018, JAMA network open.
[34] J. Hattangadi-Gluth,et al. Types and Distributions of Biomedical Industry Payments to Men and Women Physicians by Specialty, 2015 , 2017, JAMA internal medicine.
[35] Daniel M. Hartung,et al. Trends and Characteristics of US Medicare Spending on Repository Corticotropin , 2017, JAMA internal medicine.
[36] Freek Fickweiler,et al. Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians’ attitudes and prescribing habits: a systematic review , 2017, BMJ Open.
[37] J. Eloy,et al. Association of Gender With Financial Relationships Between Industry and Academic Otolaryngologists , 2017, JAMA otolaryngology-- head & neck surgery.
[38] G. Wan,et al. Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications , 2017, Advances in Therapy.
[39] James D. Murphy,et al. Types and Distribution of Payments From Industry to Physicians in 2015 , 2017, JAMA.
[40] W. J. Boscardin,et al. Financial ties of principal investigators and randomized controlled trial outcomes: cross sectional study , 2017, British Medical Journal.
[41] T. Mackey,et al. Distribution and Patterns of Industry-Related Payments to Oncologists in 2014. , 2016, Journal of the National Cancer Institute.
[42] M. Leger,et al. Exploring the Industry-Dermatologist Financial Relationship: Insight From the Open Payment Data. , 2016, JAMA dermatology.
[43] William Fleischman,et al. Industry Relationships With Pediatricians: Findings From the Open Payments Sunshine Act , 2016, Pediatrics.
[44] Daniel T Oberlin,et al. Industry Ties in Medicine: Insight from the Open Payments Program. , 2016, Mayo Clinic proceedings.
[45] M. Metersky. Is There Any Reliable Clinical Evidence to Suggest That Acthar Is More Effective Than Other Forms of Corticosteroids in Treating Sarcoidosis and Other Diseases It Is Being Marketed to Treat? , 2016, Chest.
[46] R. Sege,et al. Sex Differences in Institutional Support for Junior Biomedical Researchers. , 2015, JAMA.
[47] Evangelos Kontopantelis,et al. Regression based quasi-experimental approach when randomisation is not an option: interrupted time series analysis , 2015, BMJ : British Medical Journal.
[48] John P A Ioannidis,et al. Ensuring the integrity of clinical practice guidelines: a tool for protecting patients , 2013, BMJ : British Medical Journal.
[49] R. Jagsi,et al. Similarities and Differences in the Career Trajectories of Male and Female Career Development Award Recipients , 2011, Academic medicine : journal of the Association of American Medical Colleges.
[50] Ray Moynihan,et al. Key opinion leaders: independent experts or drug representatives in disguise? , 2008, BMJ : British Medical Journal.
[51] D. Coyne. Influence of industry on renal guideline development. , 2006, Clinical journal of the American Society of Nephrology : CJASN.
[52] G. Eknoyan,et al. National Kidney Foundation: Dialysis Outcome Quality Initiative--development of methodology for clinical practice guidelines. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[53] A. Haines,et al. Guidance on guidelines. , 1992, BMJ.
[54] J. Hattangadi-Gluth,et al. Disclosure of Industry Payments to Physicians: An Epidemiologic Analysis of Early Data From the Open Payments Program. , 2016, Mayo Clinic proceedings.
[55] J. Wootton. Clinical practice guidelines. , 1999, Journal of women's health & gender-based medicine.
[56] Reviewing the draft NKF-DOQI guidelines. 1. National Kidney Foundation-Dialysis Outcome Quality Initiative. , 1997, Nephrology news & issues.